Next 10 |
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...
2024-03-30 01:28:53 ET Summary Xeris Biopharma has not yet achieved cash flow breakeven and may no longer be a "Top Idea" in the Compounding Healthcare Investing Group. Xeris has three approved products and a strong pipeline, with potential for market penetration and revenue growt...
2024-03-28 13:11:15 ET More on Xeris Pharmaceuticals Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Phar...
2024-03-27 16:50:31 ET Gainers: Athira Pharma ( ATHA ) +5% . ContextLogic ( WISH ) +5% . Angi ( ANGI ) +4% . Xeris Biopharma Holdings ( XERS ) +4% . Inozyme Pharma ( INZY ) +3% . Losers: MillerKnoll ( ...
2024-03-06 12:52:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xeris Biopharma Holdings (NASDAQ: XERS ) just reported results for the fourth quarter of 2023. Xeris Biopharma Holdings reported earnings per share of -10 cents. This met ...
2024-03-06 12:50:02 ET Gainers: Aptorum Group Ltd ( APM ) +736% . BiomX ( PHGE ) +144% . Trxade Health ( MEDS ) +87% . New Horizon Aircraft Ltd ( HOVR ) +69% . Rail Vision Ltd ( RVSN ) +62% . Airship AI Holdings ( AISP ) ...
2024-03-06 12:43:15 ET Xeris Biopharma Holdings Inc. (XERS) Q4 2023 Earnings Conference Call March 6, 2024 8:30 am ET Company Participants Paul Edick - Chairman, Chief Executive Officer Steve Pieper - Chief Financial Officer Allison Wey - Senior Vice President, I...
2024-03-06 08:24:28 ET More on Pre-market losers & stocks. Datasea jumps 23% as subsidiary enters a potential $30M sale agreement Seeking Alpha’s Quant Rating on BeyondSpring Historical earnings data for BeyondSpring Financial information for Beyon...
2024-03-06 07:03:17 ET More on Xeris Pharmaceuticals Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Pharmaceuticals Q4 2023 Earnings Preview Amgen in pact with ...
Achieved Total Revenue of over $44M in the fourth quarter – a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achievin...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Xeris Pharmaceuticals Inc. Website:
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...
Achieved Total Revenue of over $44M in the fourth quarter – a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achievin...